Primary Intervention With Mucosal Insulin

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

January 31, 2014

Conditions
Type 1 Diabetes
Interventions
DRUG

Human Insulin

There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)

OTHER

Oral Placebo

Oral Placebo is given orally daily

Trial Locations (1)

80045

Barbara Davis Center for Childhood Diabetes, Aurora

Sponsors
All Listed Sponsors
collaborator

University Hospital Dresden

OTHER

collaborator

Diabetes Research Institute, Munich, Germany.

UNKNOWN

collaborator

University of Bristol

OTHER

collaborator

Juvenile Diabetes Research Foundation

OTHER

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

lead

University of Colorado, Denver

OTHER